Bio Essence Corp (BIOE): Operating Income
$900.0K
Year ended 2025-12-31
$1.54M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $900.0K | n/m | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | -$459.4K | n/m | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | -$345.6K | n/m | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | -$511.1K | n/c | 2024-04-15, From 2022-01-01 |
| 2021-12-31 | -$857.5K | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$832.6K | n/a | 2022-03-31, From 2020-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Bio Essence Corp (BIOE) | 2025-12-31 | $900.0K | n/m |
| Lipocine Inc. (LPCN) | 2025-12-31 | -$10.37M | n/m |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | -$177.93M | n/m |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | -$4.97M | n/m |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | -$38.31M | n/m |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | -$21.64M | n/m |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$16.22M | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | -$3.08M | n/m |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$59.91M | n/m |
Compare BIOE, LPCN, DNTH, KRSA side by side · Screen every company in Pharmaceutical Preparations ↗